Excitingly, Charles et al. reported that low-dose CDK4/6is could induce the presentation of pathway-specific MHC ligands on breast cancer cell surfaces as potential targets for immunotherapy, suggesting that low-dose CDK4/6is can be an inducer for MHC ligand expression to improve the outcomes of patients receiving immunotherapy [140]. This evidence concerns the gene HLA-C and breast carcinoma.